Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
BUSINESS
As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
Novartis’ blockbuster hopeful VEGF inhibitor Beovu (brolucizumab) is soon to hit the fridges of ophthalmic clinics in Japan following its listing earlier this week, pitting itself against market leader Eylea (aflibercept). The Swiss giant is poised to pitch its longer…
To read the full story
Related Article
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
May 13, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- Bayer’s Eylea Effective at Both 12-Week and 16-Week Intervals: PIV Study
February 13, 2020
BUSINESS
- Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President
January 30, 2025
- Jazz Obtains Pharmaceutical Marketing License in Japan
January 30, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- ASKA, Susmed Initiate Clinical Study of PMS Therapeutic App
January 29, 2025
- PeptiDream/RayzeBio’s Peptide-Radionuclide Theranostic Enter Clinic
January 29, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…